Noveris Health Sciences says USPTO issues notice of allowance for psilocin analog patent application

PUBT · 2d ago
Noveris Health Sciences says USPTO issues notice of allowance for psilocin analog patent application
  • Noveris Health Sciences received a USPTO Notice of Allowance for U.S. patent application 18/443,025 covering aza-substituted psilocin analog compounds.
  • The application includes six allowable claims; issuance remains pending payment of required issue and publication fees.
  • The company funded Applied Pharmaceutical Innovation with $146,000 to restart synthesis and testing of selected psilocybin-related compounds.
  • Work is designed to generate data to guide next R&D steps, with potential scale-up toward GMP production if candidates advance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Noveris Health Sciences Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608181705NEWSFILECNPR____20260818_310360_1) on August 18, 2026, and is solely responsible for the information contained therein.